Infectious Disease Therapy
Ramoplanin shows promise for treatment of vancomycin-resistant Enterococcus
Published in TB and Outbreaks Week, September 16th, 2003
"The prevention of vancomycin-resistant Enterococcus (VRE) colonization and infection continues to be a high priority for clinicians," scientists in the United States explained. "An oral antimicrobial agent that reduces or eliminates VRE gastrointestinal colonization could be useful for preventing VRE infection in selected patients."
"Ramoplanin, a glycolipodepsipeptide, is the first in a new class of antimicrobials," according to M.A. Montecalvo and colleagues at New York Medical College. "It has excellent in vitro activity against vancomycin-resistant...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Malaria Therapy
Adaptive inhibitor shows promise against drug-resistant malaria - Infectious Disease
Novel PCR test provides rapid Legionella detection, identification - Infectious Disease
Novel molecular assay provides rapid measure of S. aureus fluoroquinolone resistance - Malaria Proteomics
Plasmodium PfTPx-1 protein protects against oxidative, nitrosative stress - Tuberculosis Risk Factor
Interleukin-8 gene mutations can increase tuberculosis risk - AIDS Funding
Cambodia hails U.S. plan to give $22.6 million for AIDS prevention - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
